283 related articles for article (PubMed ID: 26979038)
21. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
22. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
23. Advances in antifungal therapy.
Sable CA; Strohmaier KM; Chodakewitz JA
Annu Rev Med; 2008; 59():361-79. PubMed ID: 17967129
[TBL] [Abstract][Full Text] [Related]
24. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
25. New antifungal antibiotics.
Paiva JA; Pereira JM
Curr Opin Infect Dis; 2013 Apr; 26(2):168-74. PubMed ID: 23411420
[TBL] [Abstract][Full Text] [Related]
26. Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases.
Lingegowda PB; Tan CK; Tan AL; Tan BH
Ann Acad Med Singap; 2011 Jun; 40(6):287-90. PubMed ID: 21779617
[TBL] [Abstract][Full Text] [Related]
27. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
Chitasombat MN; Kontoyiannis DP
Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
[TBL] [Abstract][Full Text] [Related]
28. Echinocandins: The Expanding Antifungal Armamentarium.
Aguilar-Zapata D; Petraitiene R; Petraitis V
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
[TBL] [Abstract][Full Text] [Related]
29. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
31. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
Schäfer-Korting M
Mycoses; 2003; 46 Suppl 1():28-31. PubMed ID: 12955850
[TBL] [Abstract][Full Text] [Related]
32. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
Klastersky J
N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
[No Abstract] [Full Text] [Related]
33. [Treatment recommendations for invasive fungal disease in pediatric patients with cancer or blood disease].
Tang S; ; ; ;
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):426-9. PubMed ID: 25190161
[No Abstract] [Full Text] [Related]
34. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin.
Alanio A; Brethon B; Feuilhade de Chauvin M; de Kerviler E; Leblanc T; Lacroix C; Baruchel A; Menotti J
Clin Infect Dis; 2008 May; 46(10):e116-8. PubMed ID: 18419477
[TBL] [Abstract][Full Text] [Related]
35. Real-world use-Isavuconazole at a large academic medical center.
Hassouna H; Athans V; Brizendine KD
Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
[TBL] [Abstract][Full Text] [Related]
36. Hope for patients with neoplastic disease and invasive fungal infections.
McLeroth P; Polsky B
J Support Oncol; 2005; 3(4):299-300. PubMed ID: 16092601
[No Abstract] [Full Text] [Related]
37. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.
Perkhofer S; Lass-Flörl C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1393-404. PubMed ID: 19656074
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
39. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
Cherif H; Kalin M; Björkholm M
Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
[TBL] [Abstract][Full Text] [Related]
40. Comment: caspofungin acetate for treatment of invasive fungal infections.
Chan J
Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
